Partial hepatectomy and liver transplantation are potentially curative treatments in selected
patients with hepatocellular carcinoma (HCC). Unfortunately, a high postoperative tumor …

Background The aim of this study was to systematically evaluate and determine those
patients with hepatocellular carcinoma (HCC) that would benefit from the administration of …

Hepatocellular carcinoma (HCC) is one of the most common and most lethal malignant
tumors in the world. Microvascular invasion (MVI) is a major risk factor for survival outcomes …

Background Microvascular invasion (MVI) has recently been reported to be an independent
prognostic factor in patients with hepatocellular carcinoma (HCC). This study compared the …

Background: Although adjuvant transcatheter arterial chemoembolization (TACE) has been
used to prevent recurrence after surgery in patients with hepatocellular carcinoma (HCC) …

Background Patients with hepatocellular carcinoma (HCC) and microvascular invasion
(mVI) have shown dismal postoperative prognosis; however, whether adjuvant transarterial …

Objective: To evaluate the efficacy and safety of adjuvant transarterial chemoembolization
(TACE) after curative hepatectomy in improving the survival of patients with primary …

Background High rates of postoperative tumor recurrence contribute to poor outcome in
hepatocellular carcinoma (HCC). Here, we investigated whether circulating tumor cells …

Purpose To evaluate the efficacy and safety of lenvatinib plus programmed death-1 (PD-1)
antibody as postoperative adjuvant therapy in patients with hepatocellular carcinoma (HCC) …

Purpose Multiple studies have demonstrated adjuvant transcatheter arterial
chemoembolization (aTACE) after resection improved outcomes compared to resection …